hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06289998 id: RP014-01 briefTitle: Study of Tamibarotene in Patients With ADPKD overallStatus: RECRUITING date: 2023-12-22 date: 2025-12 date: 2025-12 date: 2024-03-04 date: 2024-03-04 name: Rege Nephro Co., Ltd. class: INDUSTRY briefSummary: Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD) studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 70 type: ESTIMATED name: Tamibarotene name: Placebo measure: Changes in TKV from baseline measure: Changes in TLV from baseline measure: Changes in eGFR from baseline measure: Incidence of adverse events sex: ALL minimumAge: 26 Years maximumAge: 55 Years stdAges: ADULT facility: Kurume University Hospital status: RECRUITING city: Kurume state: Fukuoka zip: 830-0011 country: Japan lat: 33.31667 lon: 130.51667 facility: Hokkaido University Hospital status: RECRUITING city: Sapporo state: Hokkaido zip: 060-8648 country: Japan lat: 43.06667 lon: 141.35 facility: Shonan Kamakura General Hospital status: RECRUITING city: Kamakura state: Kanagawa zip: 247-8533 country: Japan lat: 35.30889 lon: 139.55028 facility: Toranomon Hospital Kajigaya status: RECRUITING city: Kawasaki state: Kanagawa zip: 213-8587 country: Japan lat: 35.52056 lon: 139.71722 facility: Juntendo University School of Medicine Juntendo Hospital status: RECRUITING city: Bunkyo-ku state: Tokyo zip: 113-8431 country: Japan lat: 35.37517 lon: 139.92991 facility: Toranomon Hospital status: RECRUITING city: Minato-ku state: Tokyo zip: 105-8470 country: Japan lat: 34.2152 lon: 135.1501 facility: Tokyo Women's Medical University Hospital status: RECRUITING city: Shinjukuku state: Tokyo zip: 162-8666 country: Japan lat: 35.2946 lon: 139.57059 facility: Kyoto University Hospital status: RECRUITING city: Kyoto zip: 606-8507 country: Japan lat: 35.02107 lon: 135.75385 hasResults: False
nctId: NCT06289985 id: STEP id: 1OT2NS129366-01 type: NIH link: https://reporter.nih.gov/quickSearch/1OT2NS129366-01 briefTitle: StrokeNet Thrombectomy Endovascular Platform acronym: STEP overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2028-06 date: 2028-09 date: 2024-03-04 date: 2024-03-04 name: Medical University of South Carolina class: OTHER name: National Institute of Neurological Disorders and Stroke (NINDS) name: University of Cincinnati name: University of Virginia name: Berry Consultants name: University of California, Los Angeles name: MOUNT SINAI HOSPITAL name: The Cooper Health System name: University of Pittsburgh Medical Center name: Stony Brook University name: University at Buffalo briefSummary: STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO). conditions: Ischemic Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: Adaptive Bayesian Platform Trial evaluating multiple interventions in multiple domains. primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 2000 type: ESTIMATED name: Endovascular thrombectomy with any FDA-approved category POL or NRY device name: Medical Management measure: Global disability measured by Modified Rankin Score measure: Global disability measured by Modified Rankin Score measure: Neurological deficit as measured by the National Institutes of Health Stroke Scale (NIHSS) measure: Symptomatic intracranial hemorrhage measure: Any radiologic intracranial hemorrhage measure: Mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06289972 id: HUvbayraktaroglu1 briefTitle: Development,Validity and Reliability of a Caregiver Version of the Breathlessness Beliefs Questionnaire overallStatus: RECRUITING date: 2024-02-20 date: 2025-02-20 date: 2025-02-20 date: 2024-03-04 date: 2024-03-06 name: Halic University class: OTHER briefSummary: The goal of this methodological study is to determine the reliability and validity of the The Breathlessness Beliefs Questionnaire Caregiver Version (BBQ-C) version in assessing dysfunctional breathlessness beliefs in caregivers of children with cystic fibrosis. conditions: Cystic Fibrosis conditions: Parents studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 22 type: ESTIMATED measure: The Breathlessness Beliefs Questionnaire (Caregiver Version) (BBQ-C) measure: Cystic Fibrosis Questionnaire Revised (CFQ-R) for parent version measure: Parent Attitude Scale (PAS) measure: Perceived Social Support Scale (PSS) measure: Parent Attitude Scale sex: ALL minimumAge: 25 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Haliç University status: RECRUITING city: Istanbul state: Eyup zip: 34060 country: Turkey name: Vildan Bayraktaroglu, PT, MSc role: CONTACT phone: (0212) 924 24 44 email: vildanbayraktaroglu@halic.edu.tr name: Seda Saka, PT, PhD role: PRINCIPAL_INVESTIGATOR lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06289959 id: JD-LC2023006-I01 briefTitle: Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL overallStatus: NOT_YET_RECRUITING date: 2024-02-25 date: 2029-01-01 date: 2029-01-01 date: 2024-03-04 date: 2024-03-04 name: Second Affiliated Hospital of Soochow University class: OTHER briefSummary: A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and treatment practices for DLBCL patients. conditions: Lymphoma, Large B-Cell, Diffuse studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: cfDNA measure: Progression-free survival（PFS） measure: Sensitivity, and specificity of plasma cfDNA in DLBCL patients measure: Overall survivals(OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Second Affiliated Hospital of Soochow University city: Suzhou state: Jiangsu zip: 215000 country: China name: Bingzong Li, Professor role: CONTACT phone: 0086-13776054037 email: lbzwz0907@hotmail.com lat: 31.30408 lon: 120.59538 hasResults: False
nctId: NCT06289946 id: NitroRadialLHC briefTitle: Topical Nitro or Placebo Pre-Cath overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-03-01 date: 2025-03-31 date: 2024-03-04 date: 2024-03-04 name: Thomas Jefferson University class: OTHER briefSummary: Phase 2, single-center, randomized, blinded clinical study to assess the safety and efficacy of topical nitroglycerin on ease of TRA during scheduled PCI. We will compare topical nitroglycerin to placebo applied prior to planned, non-urgent PCI to determine if nitroglycerin is associated with decreased number of arterial puncture attempts made, decreased time to radial access, and lower crossover rate to TFA. Subjects will be randomized to receive either topical nitroglycerin ointment or placebo prior to scheduled PCI. There will be 256 subjects enrolled in this study with 1:1 randomization. conditions: Coronary Artery Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 256 type: ESTIMATED name: NitroBid name: Placebo measure: Crossover rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06289933 id: BR-EMC-CT-103 briefTitle: A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fed Conditions in Healthy Adult Volunteers overallStatus: RECRUITING date: 2024-03 date: 2024-03 date: 2024-03 date: 2024-03-04 date: 2024-03-04 name: Boryung Pharmaceutical Co., Ltd class: INDUSTRY briefSummary: The objective of this clinical study is to compare the pharmacokinetics and the safety between a fixed-dose combination administration of "BR3005" and co-administration of "BR3005-1" and "BR3005-2" under fed conditions in healthy adult volunteers conditions: Type2 Diabetes Mellitus studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: BR3005 name: BR3005-1 name: BR3005-2 measure: AUCτ measure: Cmax sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinical Research Center, H PLUS Yangji Hospital status: RECRUITING city: Seoul state: Gwanakgu zip: 08779 country: Korea, Republic of name: Seunghyun Kang role: CONTACT lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06289920 id: BR-EMC-CT-102 briefTitle: A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers overallStatus: RECRUITING date: 2024-03 date: 2024-03 date: 2024-03 date: 2024-03-04 date: 2024-03-04 name: Boryung Pharmaceutical Co., Ltd class: INDUSTRY briefSummary: The objective of this clinical study is to compare the pharmacokinetics and the safety between a fixed-dose combination administration of "BR3005" and co-administration of "BR3005-1" and "BR3005-2" under fasting conditions in healthy adult volunteers conditions: Type 2 Diabetes Mellitus studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 46 type: ESTIMATED name: BR3005 name: BR3005-1 name: BR3005-2 measure: AUCτ measure: Cmax sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinical Research Center, H PLUS Yangji Hospital status: RECRUITING city: Seoul state: Gwanakgu zip: 08779 country: Korea, Republic of name: Seunghyun Kang role: CONTACT lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06289907 id: LH-BH-ADV-01 briefTitle: Hot Flash and Night Sweat Virtual Study overallStatus: ACTIVE_NOT_RECRUITING date: 2023-07-09 date: 2024-05-30 date: 2024-07-30 date: 2024-03-04 date: 2024-03-04 name: Bonafide Health class: INDUSTRY name: Lindus Health briefSummary: The purpose of this research study is to evaluate the effectiveness of the study product on vasomotor symptoms (VMS) and overall menopause symptoms in healthy women, who are perimenopausal or postmenopausal, and aged 40 - 65. conditions: Menopause studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Decentralized, double-blind, placebo-controlled, randomized primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Double-blind whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Bonafide-HF3.0 name: Placebo measure: To determine the effects of the Study Product (SP) compared to placebo on hot flash symptoms measure: To determine the effects of the SP compared to placebo on hot flash symptoms measure: To determine the effects of the SP compared to placebo on hot flash symptoms measure: To determine the effects of the SP compared to placebo on vasomotor symptoms measure: To determine the effects of the SP compared to placebo on overall menopausal symptoms measure: To determine the effects of the SP compared to placebo on overall menopausal symptoms measure: To determine the effects of the SP compared to placebo on quality of life sex: FEMALE minimumAge: 40 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lindus Health, Inc. city: London country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06289894 id: BRY805-101 briefTitle: A Study of BRY805 in Participants With Advanced Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2027-05 date: 2027-09 date: 2024-03-04 date: 2024-03-04 name: BioRay Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: This is a phase 1 open label multicenter study to evaluate safety, tolerance and the maximum tolerance of BRY805 administered intravenously (IV) once every three weeks in participants with advanced solid tumors, so as to confirm the recommended phase 2 dose of BRY805 and obtain the preliminary efficacy information of participants with advanced solid tumors. conditions: Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: BRY805 injection measure: Occurrence of Drug Limited Toxicities (DLTs) measure: Type and incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs) measure: BRY805 Serum Concentrations measure: Number of Participants with BRY805 Antibodies measure: Overall Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Progression-Free Survival (PFS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shandong Tumor hospital city: Jinan state: Shandong zip: 250117 country: China name: Jinming Yu, MD role: CONTACT phone: (+86)0531-67627156 email: sdyujinming@126.com lat: 36.66833 lon: 116.99722 hasResults: False
nctId: NCT06289881 id: SIL-026-21 briefTitle: Sildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets overallStatus: NOT_YET_RECRUITING date: 2025-02-04 date: 2025-03-11 date: 2025-03-25 date: 2024-03-04 date: 2024-03-04 name: Bio-innova Co., Ltd class: INDUSTRY briefSummary: The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 3 days washout period between the doses. conditions: Healthy Subjects studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: NONE count: 36 type: ESTIMATED name: Sildenafill-Test product name: Sildenafill-Reference product measure: Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t) measure: Maximal measured plasma concentration (Cmax) measure: Number of subjects with adverse events sex: MALE minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06289868 id: DC-TR23-0222 id: HAV-EU-11-23 type: OTHER domain: Beckman Coulter, Inc briefTitle: Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23) overallStatus: NOT_YET_RECRUITING date: 2024-02-27 date: 2024-05-27 date: 2024-08-27 date: 2024-03-04 date: 2024-03-04 name: Beckman Coulter, Inc. class: INDUSTRY briefSummary: The purpose of this study is to evaluate the clinical performance supporting that intended purpose of the Access anti-HAV as an aid in the laboratory diagnosis of HAV infection and for detection of anti-HAV after vaccination and of the Access anti-HAV IgM assay as an aid in the laboratory diagnosis of acute or recent HAV infection, on the DxI 9000 Access Immunoassay Analyzer.
This study will be used to obtain CE mark for both Access anti-HAV and anti- HAV IgM assays. conditions: HAV studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 1150 type: ESTIMATED name: Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays name: Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays measure: Access Anti-HAV diagnostic accuracy measured as sensitivity and specificity measure: Access Anti-HAV IgM diagnostic accuracy measured as sensitivity and specificity sex: ALL minimumAge: 2 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Cerba Xpert city: Frepillon zip: 95740 country: France name: Chloé Puisney, PhD role: CONTACT phone: 06.30.15.34.65 email: cpuisney@cerbaresearch.com lat: 49.05216 lon: 2.20528 facility: Eurofins Biomnis city: Ivry-sur-Seine zip: 94208 country: France name: Catherine Coignard, MD role: CONTACT phone: +33 149 59 63 37 email: catherine.coignard@biomnis.eurofinseu.com lat: 48.81568 lon: 2.38487 hasResults: False
nctId: NCT06289855 id: Parkinson's disease briefTitle: Impulse Control Disorder Among Parkinson's Disease Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-08-31 date: 2025-03-31 date: 2024-03-04 date: 2024-03-08 name: Assiut University class: OTHER briefSummary: The goal of this observational study is to learn about impulse control disorders in Parkinson's disease patients.
* Detect Relation between impulse control disorders, and other non motor and motor symptoms in Parkinson's disease patients, using clinical, neurophysiological and radiological assessment conditions: Parkinson's Disease studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 56 type: ESTIMATED name: MDS-UPDRS measure: number of patients with impulse control disorder among Parkinson's disease patients measure: percent of cognition affection, gait affection among patients with impulse control disorder among Parkinson's disease patients measure: volume of cortex and basal ganglia in patients with impulse control disorder among Parkinson's disease patients measure: cortical excitability and inhibition inpatients with impulse control disorder among Parkinson's disease patients sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06289842 id: ZU-IRB #9697 briefTitle: Accelerated Theta Burst Stimulation for Treatment of Suicidality in Depressed Patients overallStatus: RECRUITING date: 2024-02-01 date: 2025-01 date: 2026-01 date: 2024-03-04 date: 2024-03-04 name: Zagazig University class: OTHER_GOV briefSummary: The objective of this study is to investigate efficacy of accelerated theta burst stimulation (TBS) in suicidal reduction in patients with unipolar and bipolar depression conditions: Suicide and Depression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 34 type: ESTIMATED name: Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark) measure: Change in suicidal ideation and behaviors as measured by Columbia Suicide Severity Rating Scale (C-SSRS) measure: Change from baseline Montgomery-Åsberg Depression Rating Scale (MADRS) Score sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zagazig University status: RECRUITING city: Zagazig zip: 44519 country: Egypt name: Medhat M Bassiony, Professor role: PRINCIPAL_INVESTIGATOR name: Usama M Youssef, Professor role: SUB_INVESTIGATOR name: Ghada M Salah El-Deen, Professor role: SUB_INVESTIGATOR name: Hayam M El-Gohary, Professor role: SUB_INVESTIGATOR name: Alaa E Zayed, Ass.Lecturer role: SUB_INVESTIGATOR lat: 30.58768 lon: 31.502 hasResults: False
nctId: NCT06289829 id: 4-2023-1605 briefTitle: The Appropriate Remifentanil Dose for Optimal Insertion of Laryngeal Mask Airway in Adult Patients During Induction of General Anesthesia Using Remimazolam. overallStatus: RECRUITING date: 2024-03-02 date: 2025-07-29 date: 2025-07-29 date: 2024-03-04 date: 2024-03-04 name: Yonsei University class: OTHER briefSummary: The laryngeal mask airway (LMA) is an airway maintenance device that is easy to insert and has the advantage of causing less sore throat and autonomic nervous system stimulation. To appropriately insert the LMA, an adequate depth of anesthesia is essential. Various drugs have been studied for inducing anesthesia to achieve the appropriate depth for LMA insertion, and the newly developed benzodiazepine, remimazolam, is gaining attention as one of them. Remimazolam has rapid onset and recovery times, hemodynamic stability, and is often co-administered with opioids like remifentanil for more effective LMA insertion. This study aims to find the optimal dose of remifentanil for the proper insertion of the Ambu Auragain, one of the recently developed LMAs, during induction of anesthesia using remimazolam and the Biased-Coin Up-and-Down method will be used for this purpose. Starting with an initial concentration of remifentanil of 3.0 μg/mL, the success or failure of LMA insertion will determine the dosage for the next subject. Data will be collected from a total of 60 patients, and subsequent analysis will be conducted. conditions: Adult, Laryngeal Masks, Remimazolam, Remifentanil studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SEQUENTIAL primaryPurpose: OTHER masking: NONE count: 67 type: ESTIMATED name: remifentanil of the assigned dose name: Ambu Auragain for airway management measure: Success/failure of LMA insertion on the first attempt measure: Difficulty of LMA insertion measure: Optimality of the LMA insertion based on the administered remifentanil dose measure: The number of attempts required for successful LMA insertion and whether intubation was performed. measure: Air leak volume during positive-pressure ventilation measure: Systolic blood pressure measure: Heart rate measure: Patient State Index (PSI) measure: Severity of hoarseness measure: Severity of coughing measure: Severity of sore throat measure: Diastolic blood pressure sex: ALL minimumAge: 19 Years maximumAge: 64 Years stdAges: ADULT facility: Severance Hospital status: RECRUITING city: Seoul country: Korea, Republic of name: Darhae Eum, Assistant Clinical Professor role: CONTACT phone: 82-2-2228-2431 email: deum@yuhs.ac lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06289816 id: 28/01/2023 briefTitle: Spleen Preserving Surgery for Splenic Hydatidosis: A Cohort Study on Short and Long-Term Outcomes overallStatus: COMPLETED date: 2015-01-01 date: 2021-06-30 date: 2021-06-30 date: 2024-03-04 date: 2024-03-04 name: Yarmouk University class: OTHER briefSummary: This retrospective cohort study examines the effectiveness of minimally invasive spleen-preserving surgeries compared to total splenectomy for treating primary splenic hydatidosis in Jordan. Covering 18 patients from January 2015 to June 2021, the research highlights similar recurrence rates between both surgical approaches, emphasizing the benefits of spleen preservation in maintaining immune function and reducing septic risks, particularly in pediatric patients. conditions: Spleen-Preserving Surgery conditions: Echinococcus Granulosus Infection conditions: Hydatid Disease conditions: Minimally Invasive Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 18 type: ACTUAL name: Minimally Invasive Surgery measure: Incidence of Postoperative Short-Term Complications measure: Incidence of Postoperative Long-Term Complications sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Anas Aljaiuossi city: Irbid zip: 22110 country: Jordan lat: 32.55556 lon: 35.85 hasResults: False
nctId: NCT06289803 id: Huadong Hospital of FudanU briefTitle: The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery overallStatus: RECRUITING date: 2023-09-01 date: 2025-01-31 date: 2025-06-30 date: 2024-03-04 date: 2024-03-04 name: Fudan University class: OTHER briefSummary: Aim of the study: To evaluate the value of Probe Confocal Laser Endomicroscopy (PCLE) in surgery for pancreatic tumor.